Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Amgen’s Ocrelizumab Biosimilar in Phase 3 Trials

Jan 13, 2025

At the JP Morgan Annual Healthcare conference on 13 January 2025, Amgen revealed that it currently has an ocrelizumab biosimilar (ABP 692) in Phase 3 trials.  The Phase 3 study (NCT06700343), which begins enrolment this month in the US, is aimed at demonstrating pharmacokinetic and pharmacodynamic similarity between ABP 692 and Genentech’s Ocrevus® (ocrelizumab) in patients with relapsing, remitting multiple sclerosis.

Celltrion also has an ocrelizumab biosimilar in development, announcing in August 2023 that the European Medicines Agency (EMA) had partially approved its Phase 3 IND for CT-P53 (ocrelizumab).  Its study (NCT05906992), to be conducted in Poland, is currently recruiting.

Amgen has two further biosimilars in Phase 3 trials: pembrolizumab (Ph 3 in nsNSCLC initiated May 2024 for ABP 234) and nivolumab (patients enrolled in a study evaluating pharmacokinetic similarity of ABP 206 compared with BMS’ Opdivo® (nivolumab) in Q2/2024).

Amgen is expecting to launch its Wezlana®/ustekinumab (biosimilar to Janssen’s Stelara®) in the US in Q1/2025 and is planning a US-launch for Bkemv®/eculizumab (biosimilar to Alexion’s Soliris®) in Q2 2025.  Bkemv®’s US launch is subject to a settlement reached by Amgen and Alexion in May 2020.